Dr. Hundemer is a Scientist in the Inflammation and Chronic Disease Program at the Ottawa Hospital Research Institute, an Associate Professor in the Department of Medicine with cross-appointment in the School of Epidemiology and Public Health at the University of Ottawa, and a staff nephrologist at the Ottawa Hospital. He received his M.D. from Vanderbilt University (2007) and M.P.H. from Johns Hopkins University (2011). Following medical school, he served 4 years as a flight surgeon in the United States Air Force. He then completed his internal medicine residency at Massachusetts General Hospital (2015) and nephrology fellowship at the combined Massachusetts General Hospital and Brigham & Women’s Hospital Joint Nephrology Fellowship Program (2018). He has received a number of research honors including the John H. Laragh Research Award, University of Ottawa Faculty of Medicine Early Career Clinical Researcher of the Year, University of Ottawa Department of Medicine Early Career Research Award, Hypertension Canada Jacques de Champlain New Investigator Award, Canadian Society of Nephrology New Investigator Award, KRESCENT New Investigator Award, and the International Aldosterone Society Young Investigator Award. His research has been funded by CIHR, NIH, Kidney Foundation of Canada, TOHAMO, and the Lorna Jocelyn Wood Chair for Kidney Research. He also currently serves as Co-Chair for the Hypertension Canada Clinical Practice Guidelines Committee.
Goupil R, Tsuyuki RT, Santesso N, Terenzi KA, Habert J, Cheng G, Gysel SC, Bruneau J, Leung AA, Campbell NRC, Schiffrin EL,
Hundemer GL. Hypertension Canada guideline for the diagnosis and treatment of hypertension in primary care.
CMAJ. 2025; 197:E549-64.
Hundemer GL, Agharazii M, Madore F, Piché M, Gagnon C, Bussières A, St-Jean M, Leung AA, Kline GA, Sood MM, Burger D, Ramsay T, Goupil R. Sex-specific associations of aldosterone and renin with body composition: A population-based cohort study.
J Clin Endocrinol Metab. 2025; 18:110(3):801-10.
Hundemer GL, Agharazii M, Madore F, Vaidya A, Leung AA, Kline GA, Crean AM, Shaw JLV, Ramsay T, Hametner B, Wassertheurer S, Larose E, Sood MM, Hiremath S, Ruzicka M, Goupil M. Subclinical primary aldosteronism and cardiovascular health: A population-based cohort study.
Circulation. 2024; 149(2):124-34.
Hundemer GL, Leung AA, Kline GA, Brown JM, Turcu AF, Vaidya A. Biomarkers to guide medical therapy in primary aldosteronism.
Endocr Rev. 2024; 45(1):69-94.
Hundemer GL, Imsirovic H, Vaidya A, Yozamp N, Goupil R, Madore F, Agharazii M, Knoll G, Sood MM. Screening rates for primary aldosteronism among individuals with hypertension plus hypokalemia: A population-based retrospective cohort study.
Hypertension. 2022; 79(1):178-86.
Hung A, Ahmed S, Gupta A, Davis A, Kline GA, Leung AA, Ruzicka M, Hiremath S,
Hundemer GL. Performance of the aldosterone-to-renin ratio as a screening test for primary aldosteronism: A systematic review and meta-analysis. J Clin Endocrinol Metab. 2021; 106(8):2423-35.
Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study.
Lancet Diabetes Endocrinol. 2018; 6(1):51-9.
Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Incidence of atrial fibrillation and mineralocorticoid receptor activity in medically and surgically treated primary aldosteronism.
JAMA Cardiology. 2018; 3(8):768-74.
Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Renal outcomes in medically and surgically treated primary aldosteronism.
Hypertension. 2018; 72(3):658-66.
